title: Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy.
authors.affiliation: Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia. mulligan@staff.edu.au
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Mulligan
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology*; D008954:Models, Biological; D011379:Prognosis; D033581:Stem Cell Transplantation / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine